

Predictmedix Announces Results of its Annual and Special Meeting of Shareholders

written by Raj Shah | February 1, 2021

February 1, 2021 ([Source](#)) – **Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF)** (“**Predictmedix**” or the “**Company**”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on January 28, 2021 at 10:00 a.m. (the “**Meeting**”). The requisite approval of shareholders for the following items, all as more particularly described in the information circular of the Company dated December 21, 2020 (the “**Circular**”), was received at the Meeting:

1. setting the number of directors of the Company at four;
2. the re-election of Sheldon Kales, Rahul Kushwah, Tomas Sipos and Ajit Kumar as directors of the Company for the ensuing year;
3. the re-appointment of Harbourside CPA LLP (previously Buckley Dodds LLP) as the Company’s auditors; and
4. the authorization of the Company to make an application to the Supreme Court of British Columbia pursuant to Section 229 of *Business Corporations Act* (British Columbia) (“**Section 229 Application**”). The only omissions, defects, errors or irregularities the Company sought to rectify through the Section 229 Application was the Company’s failure to hold an annual general meeting during the 2019 calendar year and distribute interim and annual financial statements. There were no other undisclosed omissions, defects, errors or irregularities that Predictmedix needed to cure.

A complete copy of the Circular is available on the Company’s

SEDAR profile at www.sedar.com.

About Predictmedix Inc.

Predictmedix is an artificial intelligence (“**AI**”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

Predictmedix is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix is expanding its proprietary AI technology to screen for infectious disease symptoms.

For further information, please contact:

Ehsan Agahi, Investor Relations

Tel: 778 229 4319

Email: IR@predictmedix.com

Caution Statement Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements

should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Predictmedix assumes no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

SOURCE: PredictMedix Inc.